EvaluatePharma World Preview 2017, Outlook to 2022
Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years
The new edition of our annual report, EvaluatePharma World Preview 2017, Outlook to 2022 discusses the impact that increased scrutiny around the pricing of medicines is starting to have on drug sales growth.
Despite consensus forecasts for worldwide drug sales hitting $1.06trn in 2022, this is down from the $1.12trn analysts forecast for the same period last year. The fall also represents the first time in 10 years of Evaluate analysis that total drug sales have failed to beat previous year forecasts.
This report brings together many of our analyses to provide a top level insight, from the world's financial markets, into the expected performance of the industry between now and 2022.
Worldwide prescription drug sales forecasted to grow at a robust 6.5% (CAGR) through 2022 to reach $1.06trn
32% of the 2022 increase in sales to come from orphan drugs (+$95bn)
Sales at risk worth $194bn potentially signal a second patent cliff era with the advent of biosimilars
Novartis, Pfizer and Roche to compete head to head for the crown of worldwide RX sales in 2022, but Novartis seems to have a slight edge
Celgene (+15%) and Shire (+10%) expected to record the fastest sales growth(CAGR) by 2022 although growth estimates have been revised downward in the last 12 months
View EvaluatePharma World Preview 2017, Outlook to 2022 Executive Summary